+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 1
Age: 18Years +
All Genders
ID07156565

Open-label Study to Evaluate Safety, Dose, and Efficacy of Radiopharmaceutical Ac225RTX-2358 for Relapsed or Refractory Soft Tissue Sarcoma

Led by Ratio Therapeutics, Inc. · Updated on 2026-08-28

48

Participants Needed

6

Research Sites

208 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are studying a drug called Ac225RTX-2358 and a diagnostic imaging agent Cu64LNTH-1363S to evaluate their safety and effectiveness in treating advanced soft tissue sarcoma. This Phase 12 open-label trial focuses on patients with relapsed or treatment-resistant sarcoma. The study aims to find the safest dose of Ac225RTX-2358 and see if it can help control the sarcoma. Participants receive Ac225RTX-2358 as an intravenous injection once every 8 weeks, with up to six doses over 12 months. The trial has two phases Phase 1 uses escalating doses in three groups to identify the maximum tolerated dose, while Phase 2 evaluates the drugs efficacy and safety in up to 50 patients. Before treatment, participants undergo an imaging test with Cu64LNTH-1363S to confirm tumor protein expression. A Safety Review Committee oversees dose escalation and safety throughout the study. During the first treatment cycle, participants visit the clinic three times in the first week and weekly for seven weeks for tests and check-ups. In subsequent cycles, visits occur every two weeks. After treatment, patients enter long-term follow-up lasting up to five years to monitor safety, disease progression, and overall survival. Researchers assess side effects, tumor response, drug pharmacokinetics, radiation dosimetry, and quality of life throughout the study.

CONDITIONS

Brief Title

Actinium Therapy for Late-stage Aggressive Sarcomas

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here